Development of a simultaneous PET/microdialysis method to identify the optimal dose of 11C-raclopride for small animal imaging

In the field of small animal positron emission tomography (PET), the assumptions underlying human and primate kinetic models may not be sustained in rodents. That is, the threshold dose at which a pharmacologic response occurs may be lower in small animals. In order to define this relationship, we combined microPET imaging using 11C-raclopride with microdialysis measures of extracellular fluid (ECF) dopamine (DA). In addition, we performed a series of studies in which a known mass of raclopride was microinfused into one striatum prior to a high specific activity (SA) systemic injection of 11C-raclopride. This single-injection approach provided a high and low SA region of radiotracer binding in the same animal during the same scanning session. Our data demonstrate that the binding potential (BP) declines above 3.5 pmol/ml (0.35 microg), with an ED50 of 8.55+/-5.62 pmol/ml. These data also provide evidence that BP may be compromised by masses of raclopride below 2.0 pmol/ml (0.326 microg). Increases in ECF DA were produced by mass doses of raclopride over 3.9 pmol/ml (0.329 microg) with an ED50 of 8.53+/-2.48 pmol/ml. Taken together, it appears that an optimal range of raclopride mass exists between 2.0 and 3.5 pmol/ml, around which the measured BP can be compromised by system sensitivity, endogenous DA, or excessive competition with unlabeled compound.

[1]  Svetlana I. Chefer,et al.  Limitations of Binding Potential as a Measure of Receptor Function: A Two-Point Correction for the Effects of Mass , 1998 .

[2]  A. Gjedde,et al.  Quantification of Neuroreceptors in Living Human Brain. V. Endogenous Neurotransmitter Inhibition of Haloperidol Binding in Psychosis , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  R. Leahy,et al.  High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner. , 1998, Physics in medicine and biology.

[4]  D J Brooks,et al.  Effect of L‐dopa and 6‐hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET , 1995, Synapse.

[5]  N. Volkow,et al.  Positron emission tomography (PET) studies of dopaminergic/cholinergic interaction in the baboon brain , 1990, Synapse.

[6]  Adriaan A. Lammertsma,et al.  The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease , 1996, Journal of Neuroscience Methods.

[7]  Arthur W. Toga,et al.  A 3D digital map of rat brain , 1995, Brain Research Bulletin.

[8]  K. Schäfers,et al.  Imaging small animals with positron emission tomography , 2003, Nuklearmedizin.

[9]  R. V. Van Heertum,et al.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. Müller-Gärtner,et al.  Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Positron emission tomography receptor assay with multiple ligand concentrations: an equilibrium approach. , 2004, Methods in enzymology.

[12]  Ella Hirani,et al.  Temporal characterisation of amphetamine‐induced dopamine release assessed with [11C]raclopride in anaesthetised rodents , 2004, Synapse.

[13]  J S Fowler,et al.  Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels , 1993, Synapse.

[14]  S. Cherry,et al.  Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals , 1999, Gene Therapy.

[15]  G. Sedvall,et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.

[16]  H. Müller-Gärtner,et al.  Imaging of striatal dopamine D(2) receptors with a PET system for small laboratory animals in comparison with storage phosphor autoradiography: a validation study with (18)F-(N-methyl)benperidol. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  R. Myers Quantification of brain function using PET , 1996 .

[19]  Adriaan A. Lammertsma,et al.  CHAPTER 3 – Quantification of Dopamine Receptors and Transporter in Rat Striatum Using a Small Animal PET Scanner , 1996 .

[20]  J S Fowler,et al.  Concentration and occupancy of dopamine transporters in cocaine abusers with [11C]cocaine and PET , 1997, Synapse.

[21]  M. Daube-Witherspoon,et al.  Quantitative functional brain imaging with positron emission tomography , 1998 .

[22]  M. Beu,et al.  In Vivo Measurement of D 2 Receptor Density and Affinity for 18 F-( 3N-Methyl ) Benperidol in the Rat Striatum with a PET System for Small Laboratory Animals , 2003 .

[23]  M. Beu,et al.  In vivo measurement of D2 receptor density and affinity for 18F-(3-N-methyl)benperidol in the rat striatum with a PET system for small laboratory animals. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  H. Benveniste Brain Microdialysis , 1989, Journal of neurochemistry.

[25]  J Delforge,et al.  Absolute Quantification by Positron Emission Tomography of the Endogenous Ligand , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  Simon R. Cherry,et al.  In vivo imaging of neuronal activation and plasticity in the rat brain by high resolution positron emission tomography (microPET) , 2000, Nature Biotechnology.

[27]  Simon R. Cherry,et al.  Deficits in Striatal Dopamine D2 Receptors and Energy Metabolism Detected by in Vivo MicroPET Imaging in a Rat Model of Huntington's Disease , 2000, Experimental Neurology.

[28]  S. Hume,et al.  Modulatory effects of L-DOPA on D2 dopamine receptors in rat striatum, measured using in vivo microdialysis and PET , 1998, Journal of Neural Transmission.

[29]  P F Morrison,et al.  Steady-state theory for quantitative microdialysis of solutes and water in vivo and in vitro. , 1990, Life sciences.

[30]  D. Alexoff,et al.  Topiramate selectively attenuates nicotine‐induced increases in monoamine release , 2001, Synapse.

[31]  Doris J Doudet,et al.  In Vivo Measurement of Receptor Density and Affinity: Comparison of the Routine Sequential Method with a Nonsequential Method in Studies of Dopamine D2 Receptors with [11C]Raclopride , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[32]  J. Brodie,et al.  Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: a PET/microdialysis study. , 2000, Life sciences.

[33]  S R Meikle,et al.  The influence of tomograph sensitivity on kinetic parameter estimation in positron emission tomography imaging studies of the rat brain. , 2000, Nuclear medicine and biology.

[34]  Karmen K. Yoder,et al.  Estimation of local receptor density, B'max, and other parameters via multiple-injection positron emission tomography experiments. , 2004, Methods in enzymology.

[35]  Jean Logan,et al.  Reproducibility of 11C-raclopride binding in the rat brain measured with the microPET R4: effects of scatter correction and tracer specific activity. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  Roger N. Gunn,et al.  Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals , 1998, European Journal of Nuclear Medicine.